Newsfeeds - Spark Newswire

1 minute read

FDA
News

Blueprint Medicines’ Ayvakyt Receives European Commission Approval For The Treatment Of Adults With Advanced Systemic Mastocytosis

Today, 11:13 AM

Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that the European Commission (EC) has expanded the current indication for AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult

BPMC

1 minute read

Stifel Maintains Buy on Blueprint Medicines, Raises Price Target to $105

By Benzinga Newsdesk

Today, 11:13 AM

Stifel analyst Bradley Canino maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $100 to $105.

BPMC

7 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 11:13 AM

During Tuesday's trading, 98 companies set new 52-week lows.

AAON

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For March 1, 2022

By Benzinga Insights

Today, 11:13 AM

Upgrades

ACLX

1 minute read

Citigroup Initiates Coverage On Blueprint Medicines with Neutral Rating

By Benzinga Newsdesk

Today, 11:13 AM

Citigroup analyst David Lebowitz initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Neutral rating.

BPMC

1 minute read

Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies

By Vandana Singh

Today, 11:13 AM

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a

BPMC

30 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 11:13 AM

During Tuesday's trading, 505 companies set new 52-week lows.

ACRX

1 minute read

HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Lowers Price Target to $100

By Benzinga Newsdesk

Today, 11:13 AM

HC Wainwright & Co. analyst Andrew Fein maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and lowers the price target from $135 to $100.

BPMC

4 minute read

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna’s Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa

By Shanthi Rexaline

Today, 11:13 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ALKS

10 minute read

Earnings Scheduled For February 16, 2022

By Benzinga Insights

Today, 11:13 AM

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.

ACVA